Beta‐blockers for treatment of autoimmune blistering dermatosis

Abdelmaksoud, Ayman; Vestita, Michelangelo

doi:10.1111/jdv.15054

Cited by 3 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…β-Blockers have been successfully used in dermatoses such as hemangiomas, kaposiform haemangioendothelioma, pyogenic granulomas, erythemato-telangiectatic rosacea, angiolymphoid hyperplasia with eosinophillia. There have been promising results in adrenergic urticaria, aquagenic pruritus, wound healing, pemphigus vulgaris, other autoimmune blistering diseases and potentially in melanoma (58,59).…”

Section: Cutaneous Side - Effects Of β-Blockersmentioning

confidence: 99%

Immunologic adverse reactions of β-blockers and the skin (Review)

Tatu¹,

Elisei²,

Chioncel

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

β-Blockers are a widely utilised class of medication. They have been in use for a variety of systemic disorders including hypertension, heart failure and intention tremors. Their use in dermatology has garnered growing interest with the discovery of their therapeutic effects in the treatment of haemangiomas, their potential positive effects in wound healing, Kaposi sarcoma, melanoma and pyogenic granuloma, and, more recently, pemphigus. Since β-blockers are deployed in a variety of disorders, which have cutaneous co-morbidities such as psoriasis, their pertinence to dermatologists cannot be overstated. Likewise, β-blockers, like any other drug category, carry risks of side effects, some of which are dermatologic. These include triggering and exacerbation of psoriasis, psoriatic and rheumatoid arthritis, anaphylaxis, contact dermatitis, occupational contact dermatitis, Raynaud's disease, alopecia, lichen planus-like drug eruption, hyperhydrosis and vitiligo. While recent articles have focussed on the positive uses of β-blockers, it may also be wise to call our attention to the potential dermatologic adverse effects that may follow β-blocker use, as well as possible therapeutic approaches to these. This short review will focus on those dermatoses resulting from β-blocker use, which have an immunologic basis.

show abstract

Section: Cutaneous Side - Effects Of β-Blockersmentioning

confidence: 99%

Immunologic adverse reactions of β-blockers and the skin (Review)

Tatu¹,

Elisei²,

Chioncel

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Abdelmaksoud and Vestita regarding our study about the in situ expression of vascular endothelial growth factor (VEGF) and endoglin in patients with pemphigus foliaceus (PF) and pemphigus vulgaris. 1 We proposed that the severity of PF is related not only to the level of circulating autoantibodies but also to the ability to restore tissue integrity following intraepidermal detachment. We have demonstrated that overexpression of VEGF is observed both in serum samples 2 and skin fragments obtained from patients with severe PF, 3 and suggested the use of b-blockers to regulate it.…”

Section: Dear Editormentioning

confidence: 99%

“…Clinically, it has four stages: primary, secondary, latent and tertiary. 1,2 In most instances, the diagnosis is made during the secondary stage, on which lesions are more numerous, symptomatic, and may affect skin and mucosa areas simultaneously. On the other hand, the primary stage manifests by single, usually painless, ulceration that goes into spontaneously healing between 2-4 weeks after its appearance.…”

Section: Dear Editormentioning

confidence: 99%